Legend Biotech CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
FMR LLC, through its subsidiaries, has disclosed beneficial ownership of 15.0% of Legend Biotech Corp.'s common stock as of June 30, 2026.
NASDAQ
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a combined beneficial ownership of 13.1% in Legend Biotech Corp's Ordinary Shares as of December 31, 2025.
NASDAQ
FMR LLC and Abigail P. Johnson have reported beneficial ownership of 15.0% of Legend Biotech Corp's common stock, totaling over 55 million shares.
NASDAQ
FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 13.9% in Legend Biotech Corp, holding over 51 million common shares as of June 30, 2025.
NASDAQ
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a combined beneficial ownership of 10.9% in Legend Biotech Corp, totaling over 40 million shares.
NASDAQ
T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, disclosing a 3.7% beneficial ownership stake in Legend Biotech Corp-ADR as of December 31, 2024.
NASDAQ
FMR LLC and its affiliates, along with Abigail P. Johnson, have reported a beneficial ownership of 7.3% in Legend Biotech Corp's common stock as of December 31, 2024.